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Abstract
Background: Primary melanocytic neoplasms are rare in the pediatric age. Among them, the pattern of neoplastic
meningitis represents a peculiar diagnostic challenge since neuroradiological features may be subtle and
cerebrospinal fluid analysis may not be informative. Clinical misdiagnosis of neoplastic meningitis with tuberculous
meningitis has been described in few pediatric cases, leading to a significant delay in appropriate management of
patients. We describe the case of a child with primary leptomeningeal melanoma (LMM) that was initially
misdiagnosed with tuberculous meningitis. We review the clinical and molecular aspects of LMM and discuss on
clinical and diagnostic implications.
Case presentation: A 27-month-old girl with a 1-week history of vomiting with mild intermittent strabismus
underwent Magnetic Resonance Imaging, showing diffuse brainstem and spinal leptomeningeal enhancement.
Cerebrospinal fluid analysis was unremarkable. Antitubercular treatment was started without any improvement. A
spinal intradural biopsy was suggestive for primary leptomeningeal melanomatosis. Chemotherapy was started, but
general clinical conditions progressively worsened and patient died 11 months after diagnosis. Molecular
investigations were performed post-mortem on tumor tissue and revealed absence of BRAFV600E, GNAQQ209 and
GNA11Q209 mutations but the presence of a NRASQ61K mutation.
Conclusions: Our case adds some information to the limited experience of the literature, confirming the presence
of the NRASQ61K mutation in children with melanomatosis. To our knowledge, this is the first case of
leptomeningeal melanocytic neoplasms (LMN) without associated skin lesions to harbor this mutation. Isolated LMN
presentation might be insidious, mimicking tuberculous meningitis, and should be suspected if no definite
diagnosis is possible or if antitubercular treatment does not result in dramatic clinical improvement.
Leptomeningeal biopsy should be considered, not only to confirm diagnosis of LMN but also to study molecular
profile. Further molecular profiling and preclinical models will be pivotal in testing combination of target therapy to
treat this challenging disease.
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Background
Primary melanocytic neoplasms are rare in the pediatric
age and may present with a wide spectrum of clinical
and pathological features [1]. Among them, the pattern
of neoplastic meningitis represents a peculiar diagnostic
challenge since the neuroradiological features may be
subtle and cerebrospinal fluid (CSF) analysis may not be
informative [1]. Clinical misdiagnosis of neoplastic men-
ingitis with tuberculous meningitis has been described in
few pediatric cases, leading to a significant delay in ap-
propriate management of patients (Table 1) [2–7].
We describe the case of a child with primary lepto-
meningeal melanoma (LMM) that was initially misdiag-
nosed with tuberculous meningitis. We review clinical
and molecular aspects of LMM and discuss clinical and
diagnostic implications.
Case presentation
A 27- month-old girl was referred to Bambino Gesù
Children's Hospital in 2009 after a 1-week history of
vomiting associated to mild intermittent strabismus.
Ophthalmologic evaluation revealed bilateral papille-
dema. Magnetic Resonance Imaging (MRI) showed dif-
fuse brainstem and spinal leptomeningeal enhancement
(Fig. 1a–c). CSF analysis was unremarkable. Tuberculosis
(TB) was not confirmed by a complete work-up. None-
theless, antitubercular treatment was started based on
the MRI findings. After 10 days the patient was trans-
ferred to the Intensive Care Unit for a salt wasting syn-
drome. A new MRI demonstrated hydrocephalus
(Fig. 1d) and progression of leptomeningeal enhance-
ment (Fig. 1e–g). A new CSF examination was done and
showed neoplastic cells with large cytoplasm and prom-
inent nucleoli (Fig. 2) positive for S100. Therefore,
antitubercular therapy was discontinued and a ventricu-
loperitoneal shunt was placed because of the progression
of neurological symptoms. Moreover, a spinal intradural
biopsy was performed: histological examination showed
pleomorphic cells with vesicular nuclei, eosinophilic
nuclear pseudoinclusion and moderate cytoplasm (Fig. 3).
Immunohistochemistry showed intense positivity for
MelanA, suggesting the diagnosis of primary leptomen-
ingeal melanomatosis. No signs of cutaneous melanosis
were observed. Chemotherapy was started, including
temozolomide, cis-platinum, vindesine and peg-
interferon alfa-2b. MRI was obtained every two months
showing stable disease until the sixth course of chemo-
therapy when progression was found. At that time, radi-
ation was associated to peg-interferon alfa-2b but the
tumor rapidly spread to chest and abdomen. General
clinical conditions progressively worsened and patient
died 11 months after diagnosis. Molecular investigations
were performed post-mortem on tumor tissue and
revealed absence of BRAFV600E, GNAQQ209 and
GNA11Q209 mutations but the presence of a NRASQ61K
mutation.
Conclusions
Primary leptomeningeal melanocytic neoplasms (LMN)
can be focal (melanomas) or diffuse (melanomatosis) [8].
Since the first description by Virchow in 1859 [9], pri-
mary LMM has been reported in few hundreds of pa-
tients, mainly adults, with peak incidence in the fourth
decade of life [2, 10, 11]. Pediatric experience is ex-
tremely limited, accounting for about 0.1 % of central
nervous system tumors, this affecting the diagnostic ap-
proach and clinical management of patients. During em-
bryogenesis, melanocytic precursors spread from the
neural crest to the skin. Few cells can also be found in
mucosae, eyes and leptomeninges, explaining primary
extracutaneous localizations of melanomas.
Isolated LMNs are a challenging diagnosis in children
because they are usually found in association to cutane-
ous melanomatosis. As previously reported, neurologic
signs and symptoms of primary LMM are nonspecific,
including seizures, psychiatric disturbances, and signs
and symptoms of raised intracranial pressure, often with
rapid evolution and fatal course [2]. Unlike most other
cerebral tumors, the classic MRI appearance of LMM
consists in high signal intensity on T1-weighted images
and low signal intensity on T2-weighted images, depend-
ing on the presence of free paramagnetic radicals from
melanin. Nonetheless, different signal patterns may be
observed because of intratumoral hemorrhage [11]. A
milestone in the characterization of cutaneous melan-
oma is the finding of the BRAFV600E mutation in over
50 % of cases. Few molecular data are available about
LMN making diagnosis challenging both on the clinical
and pathological side [12].
Recent data suggest the presence of specific mutations
in diffuse melanomatosis. Interestingly, different muta-
tions have been found in adults (GNAQ and GNA11
mutations) and children (NRASQ61K), with BRAFV600E
mutation being observed in only 2 % of adult cases. In
the largest series of children with cutaneous melanoma-
tosis, 51 out of 66 were found to have the NRASQ61K
mutation in their lesions [13]. Notably, in children with
the neurocutaneous form (12 out of 16), the same muta-
tion was found in leptomeningeal lesions suggesting a
common origin of neoplastic precursors [14–16]. It has
been suggested that a post-zygotic NRAS mutation of
neural crest cells during embryogenesis, before migra-
tion to skin and leptomeninges, might condition a NRAS
mosaicism in the same organism [17]. Nonetheless, mu-
tations occurring before commitment to the neural crest
lineage might explain the detection of the same NRAS
mutation in tumors other than melanocytic. Interest-
ingly, a NRASQ61R mutation has been reported in a
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Table 1 Pediatric case reports of primary leptomeningeal melanoma and neoplastic meningitis mimicking tuberculous meningitis
Reference Makin, 1999 Nicolaides, 1995 Selcuk, 2008 Demir, 2010 Kosker, 2014 Erdogan, 2014 Our patient
Diagnosis Primitive leptomeningeal
melanoma
Primitive leptomeningeal
melanoma
Atypical Teratoid
Rhabdoid Tumor
Spinal low-grade
neoplasm
Primary diffuse
leptomeningeal
gliomatosis
Primary spinal
leptomeningeal
gliomatosis
Primitive leptomeningeal
melanoma
Age and Sex 5,5 years, Male 5 years, Male 6 years, Female 8 years, Female 3 years, male 3 years, male 2 years, Female
Onset signs
and symptoms
13-week history of
headaches, vomiting,
and weight loss
followed by acute
deterioration of
conscious level
3-month history of vomiting,
anorexia, and weight loss, 1-
month history of headaches
and pyrexia, acute deterioration
of conscious level
2-months
history of
confusion,
headache,
vomiting,
aphasia, and
right
hemiparesis
History of
headache,
nausea, fever,
and vomiting,
followed by
double vision
3-month history of
strabismus and 1-week
history of headache and
restlessness
Deviation of left eye,
weakness, lack of
appetite, headache and
behavioral change
1-week history of vomiting
Imaging at
onset
CT: diffuse meningeal
enhancement
CT: diffuse meningeal
enhancement
MRI: marked
leptomeningeal
involvement
and basal
meningitis
MRI:
communicating
hydrocephalus,
diffuse
leptomeningeal
enhancement at
basal cisterns
MRI: leptomeningeal
infiltration, prominent
around the Sylvian
fissure and at the level
of the basal cisterns
MRI: diffuse
leptomeningeal
enhancement,
predominantly involving
the basal cisterns and
hydrocephalus
MRI: enhancement of the
cervical and basal meninges
and cranial nerves, in addition
to a small focal enhancement
anterior to the pons
CSF analysis at
onset
- Protein 1.5 g/dL
- Glucose 0.7 mmol/L
- No cells
- Protein 1.5 g/L
- Glucose 0.5 mmol/L
(serum glucose 5 mmol/L)
- Leukocytes 36/mm3
- Protein
40.8 mg/dL
- Glucose
36 mg/dL
(serum glucose
136 mg/dL)
- Lymphocytes
350/mm3
- Protein
242 mg/dL
- Glucose 74 mg/
dL
(serum glucose
116 mg/dL)
- 10 × 5 cells
(60 %
lymphocyte,
40 % PMNL)
- Protein 9.2 mg/dL
- Glucose 102 mg/dL
(serum glucose 136 mg/
dL)
- Leukocytes 470/mm3
(90 % lymphocyte, 10 %
PMNL)
- Protein elevated
- Glucose normal
- Protein 62 mg/dL
- Glucose 83 mg/dL
(serum glucose 133 mg/dL)
- Leukocytes 2/mm3
CSF cyto-
morphological
examination
ND - 1st sample: negative
- 2nd sample: positive for
malignant cells
Negative ND Negative Negative - 1st sample:
negative
- 2rd sample: positive for
malignant cells
Time delay
between onset
of symptoms
and definitive
diagnosis
3 months 3 months UNK 4 months 10 months 4 months 10 weeks
Chemotherapy Vincristine, carboplatin,
and etoposide
Chemotherapy according to
local protocol (not specified)
Not done
(parent’s refusal)
Cisplatin and
etoposide;
radiotherapy
Vincristine, carboplatin,
and etoposide; (parents
refused radiotherapy)
Vincristine and
carboplatin
Temozolomide, cis-platinum,
vindesina and peginterferon
alfa-2b; radiotherapy
Outcome Dead 6 months after
diagnosis
Unknown Dead 3 months
after onset
Alive after
19 months
follow-up
Alive after 18 months
follow-up
Unknown Dead 11 months after
diagnosis
CSF, cerebrospinal fluid, CT computed tomography, MRI magnetic resonance imaging, ND not done, UNK unknown, PMNL polymorphonuclear leukocytes
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spinal neurocristic hamartoma associated to NCM and
leptomeningeal melanocytosis by Kinsler et al. Other ob-
served tumors include meningioma and choroid plexus
papilloma. Shih et al. reported a NRASG13R mutation in
a primary mesenchimal brain neoplasm [18]. Invariably,
the same mutation was documented in associated CMN
but the observation of a germline single-nucleotide poly-
morphism of the MET gene suggests the possibility of a
second hit to condition the clinical picture. In fact,
NRAS mutations do not result in melanoma according
to in vitro and in vivo preclinical models and to the evi-
dence of mutated cells in CMN [19]. Possible co-
operators in melanoma development include MET and
CDKN2A [15, 20, 21].
Our case adds some information to the limited experi-
ence of the literature, confirming the presence of the
NRASQ61 mutation in children with meningeal melano-
matosis. To our knowledge, this is the first case of LMN
without associated skin lesions to harbor this mutation.
Despite thorough clinical examination we cannot ex-
clude the possibility of cutaneous melanoma having been
overlooked in our patient. Nonetheless, cutaneous mela-
nomas have also been described to regress spontan-
eously. Our child was initially treated for tuberculous
meningitis based on MRI picture. LMNs have typically
been described to show T1 hyperintensity and T2
hypointensity on baseline MRI [22]. Our patient did not
show these features, making the diagnosis of infective
Fig. 2 Cyto-morphological examination of CSF. May-Grünwald-Giemsa staining shows numerous polymorphic cells with large cytoplasm and
prominent nucleoli (a). On immunohistochemical profile cells are positive for S100 (b)
Fig. 1 Clinical onset MRI (a, b, c). Follow-up MRI (d, e, f, g). T1 axial basal image (a): no evidence of LMM’s typical hyperintensities. T1 Contrast
enhancement images (b, c): intense base and peri-spinal leptomeningeal enhancement and nodular pontine enhancing lesion (white arrow);
(e, f, g) increase of enhancing lesions. T1 axial (a, d): progressive hydrocephalus
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meningitis more appealing in the first instance, even in
presence of a negative work-up for TB. We would rec-
ommend reconsideration of diagnosis in case of suspect
TB showing clinical-radiological progression during
anti-tubercular treatment. Biopsy should be considered,
not only to confirm diagnosis of LMN but also to study
molecular profile and guide target therapy. NRAS inhibi-
tors are not currently available but downstream path-
ways, such as MAPK and PI3K/AKT/mTOR constitute
possible targets. In fact, promising results have been re-
ported both in vitro and in vivo [16, 23–27]. Multi-
target combinational approaches might help overcome
resistance to treatment, however their clinical signifi-
cance remains to be further determined [23, 24, 27–29].
Primary LMNs constitute a wide family of rare tumors.
Peculiar pathogenetic mutations have been described in
the adult (GNAQ and GNA11) and pediatric (NRAS)
population. Most LMN present in association to cutane-
ous melanosis (NCM, CMN) and, in fact, a common
molecular signature has been demonstrated in these cell
populations. Our case is, to our knowledge, the first re-
port of a LMN not associated to cutaneous findings but
sharing the same NRASQ61 mutation widely reported in
the literature. Isolated LMN presentation might be in-
sidious, mimicking TB meningitis, and should be sus-
pected if no definite diagnosis is possible or if anti-TB
treatment does not result in dramatic clinical improve-
ment. Further molecular profiling and preclinical models
will be pivotal in testing combination of target therapy
to treat this challenging disease.
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Fig. 3 Histological examination of tumor biopsy. Neoplasm is composed of pleomorphic cells with vescicular nuclei, eosinophilic nuclear
pseudoinclusion and moderate cytoplasm (a). Immunoistochemistry shows intense positivity for MelanA (b)
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